CU20140096A7 - Fenilimidazopirazoles sustituidos y su uso - Google Patents

Fenilimidazopirazoles sustituidos y su uso

Info

Publication number
CU20140096A7
CU20140096A7 CU2014000096A CU20140096A CU20140096A7 CU 20140096 A7 CU20140096 A7 CU 20140096A7 CU 2014000096 A CU2014000096 A CU 2014000096A CU 20140096 A CU20140096 A CU 20140096A CU 20140096 A7 CU20140096 A7 CU 20140096A7
Authority
CU
Cuba
Prior art keywords
diseases
phenylimidazopirazoles
replaced
prevention
preparation
Prior art date
Application number
CU2014000096A
Other languages
English (en)
Inventor
Frank Süssmeier
Mario Lobell
Sylvia Grünewald
Michael Härter
Bernd Buchmann
Joachim Telser
Hannah Jörissen
Mélanie Héroult
Antje Kahnert
Klemens Lustig
Niels Lindner
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47594775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20140096(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of CU20140096A7 publication Critical patent/CU20140096A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a nuevos derivados de 1- fenil- 1-H- imidazo [1,2-b] pirazol, a procedimientos para su preparación, a su uso para el tratamiento y/o la prevención de enfermedades así como a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, en particular de enfermedades angiogénicas y de enfermedades hiperproliferativas en las que es importante la neovascularización, como por ejemplo, enfermedades cancerosas y tumorales. Tales tratamientos pueden realizarse como monoterapia o también en combinación con otros medicamentos u otras medidas terapéuticas.
CU2014000096A 2012-01-25 2014-07-28 Fenilimidazopirazoles sustituidos y su uso CU20140096A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152515 2012-01-25
PCT/EP2013/051106 WO2013110590A1 (de) 2012-01-25 2013-01-22 Substituierte phenylimidazopyrazole und ihre verwendung

Publications (1)

Publication Number Publication Date
CU20140096A7 true CU20140096A7 (es) 2015-02-26

Family

ID=47594775

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2014000096A CU20140096A7 (es) 2012-01-25 2014-07-28 Fenilimidazopirazoles sustituidos y su uso

Country Status (31)

Country Link
US (2) US20150005288A1 (es)
EP (1) EP2807162B1 (es)
JP (1) JP6101290B2 (es)
KR (1) KR20140117582A (es)
CN (1) CN104411707B (es)
AP (1) AP2014007869A0 (es)
AR (1) AR089788A1 (es)
AU (1) AU2013211707A1 (es)
BR (1) BR112014018450A8 (es)
CA (1) CA2862163A1 (es)
CL (1) CL2014001959A1 (es)
CO (1) CO7101244A2 (es)
CR (1) CR20140362A (es)
CU (1) CU20140096A7 (es)
DO (1) DOP2014000173A (es)
EA (1) EA201491427A1 (es)
EC (1) ECSP14010868A (es)
ES (1) ES2639338T3 (es)
GT (1) GT201400161A (es)
HK (1) HK1203198A1 (es)
IL (1) IL233652A0 (es)
MA (1) MA35877B1 (es)
MX (1) MX2014008893A (es)
PE (1) PE20142421A1 (es)
PH (1) PH12014501687A1 (es)
SG (1) SG11201404118XA (es)
TN (1) TN2014000320A1 (es)
TW (1) TW201343649A (es)
UY (1) UY34590A (es)
WO (1) WO2013110590A1 (es)
ZA (1) ZA201405392B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110590A1 (de) * 2012-01-25 2013-08-01 Bayer Pharma Aktiengesellschaft Substituierte phenylimidazopyrazole und ihre verwendung
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
CN107873027A (zh) 2014-11-06 2018-04-03 巴斯夫欧洲公司 用于防治无脊椎动物害虫的3‑吡啶基杂双环化合物
MX2018004185A (es) * 2015-10-08 2018-11-09 Fmc Corp Pesticidas de azoles biciclicos sustituidos con heterociclos.
UY38366A (es) * 2018-09-13 2020-04-30 Syngenta Participations Ag Compuestos de azol-amida pesticidamente activos
CN109096195A (zh) * 2018-09-27 2018-12-28 上海雅本化学有限公司 一种艾曲波帕的制备方法
WO2021074108A1 (de) * 2019-10-16 2021-04-22 Bayer Aktiengesellschaft Verfahren zur herstellung von 1,1'-disulfandiylbis(4-fluor-2-methyl-5-nitrobenzol)
US20230145003A1 (en) * 2020-01-29 2023-05-11 Foghorn Therapeutics Inc. Compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753730B2 (ja) * 1988-07-26 1995-06-07 三共株式会社 イミダゾピラゾール誘導体
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
JP5744859B2 (ja) * 2009-06-15 2015-07-08 ライジェル ファーマシューティカルズ， インコーポレイテッド 脾臓チロシンキナーゼ（ｓｙｋ）の小分子阻害薬
KR101116756B1 (ko) * 2009-10-27 2012-03-13 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
WO2013110590A1 (de) * 2012-01-25 2013-08-01 Bayer Pharma Aktiengesellschaft Substituierte phenylimidazopyrazole und ihre verwendung

Also Published As

Publication number Publication date
ES2639338T3 (es) 2017-10-26
DOP2014000173A (es) 2014-08-31
MA35877B1 (fr) 2014-12-01
JP6101290B2 (ja) 2017-03-22
CN104411707B (zh) 2017-03-01
PH12014501687A1 (en) 2014-10-20
EA201491427A1 (ru) 2015-01-30
GT201400161A (es) 2015-03-05
CL2014001959A1 (es) 2014-11-07
CR20140362A (es) 2014-08-21
AU2013211707A1 (en) 2014-08-07
WO2013110590A1 (de) 2013-08-01
US20150005288A1 (en) 2015-01-01
PE20142421A1 (es) 2015-01-11
CO7101244A2 (es) 2014-10-31
EP2807162A1 (de) 2014-12-03
MX2014008893A (es) 2014-08-26
JP2015504904A (ja) 2015-02-16
ZA201405392B (en) 2015-12-23
AP2014007869A0 (en) 2014-08-31
CA2862163A1 (en) 2013-08-01
HK1203198A1 (en) 2015-10-23
BR112014018450A2 (es) 2017-06-20
US9394309B2 (en) 2016-07-19
AR089788A1 (es) 2014-09-17
KR20140117582A (ko) 2014-10-07
ECSP14010868A (es) 2015-12-31
SG11201404118XA (en) 2014-10-30
TN2014000320A1 (en) 2015-12-21
BR112014018450A8 (pt) 2017-07-11
IL233652A0 (en) 2014-08-31
TW201343649A (zh) 2013-11-01
US20130190290A1 (en) 2013-07-25
CN104411707A (zh) 2015-03-11
UY34590A (es) 2013-09-02
EP2807162B1 (de) 2017-06-07

Similar Documents

Publication Publication Date Title
CU20140096A7 (es) Fenilimidazopirazoles sustituidos y su uso
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
IL239488A0 (en) A gpc3-targeted medicinal agent for the treatment of patients for whom treatment with a gpc3-targeted medicinal agent is beneficial
SV2015004969A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
AR089252A1 (es) Conjugados de principio activo-ligante (adc) y su uso
BR112014031088A8 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
CR20140513A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
UY35652A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
UY35055A (es) Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf
DOP2012000284A (es) Heterociclilbencilpirazoles sustituidos y uso de los mismos
BR112015006363A2 (pt) combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
UY36408A (es) Derivados de pirido benzodiazepina sustituidos y su utilización
BR112015011099A2 (pt) Composições e métodos para o tratamento de diplasia ectodérmica
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
BR112015022000A8 (pt) preparação de combinação farmacêutica, composição farmacêutica e uso da preparação de combinação
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".